Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

156.42
+2.471.60%
Post-market: 156.420.00000.00%19:58 EST
Volume:3.01M
Turnover:467.57M
Market Cap:298.45B
PE:21.88
High:156.62
Open:154.03
Low:153.90
Close:153.95
52wk High:156.62
52wk Low:97.72
Shares:1.91B
Float Shares:1.82B
Volume Ratio:1.00
T/O Rate:0.17%
Dividend:3.86
Dividend Rate:2.47%
EPS(TTM):7.15
EPS(LYR):7.15
ROE:30.81%
ROA:10.34%
PB:6.47
PE(LYR):21.88

Loading ...

Novartis breaks ground on biomedical research center in San Diego

TIPRANKS
·
Yesterday

Blood Tests and Better-for-You Soda: Super Bowl Ads May Be Healthiest Yet -- WSJ

Dow Jones
·
Feb 06

Novartis Submits Application in China for Groundbreaking Autoimmune Drug

Stock News
·
Feb 06

Novartis price target lowered to CHF 132 from CHF 133 at Citi

TIPRANKS
·
Feb 06

Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value

TIPRANKS
·
Feb 05

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead

Benzinga
·
Feb 05

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

TIPRANKS
·
Feb 04

Dow Jones Top Company Headlines at 7 AM ET: Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints | GE ...

Dow Jones
·
Feb 04

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

Dow Jones
·
Feb 04

Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk

Dow Jones
·
Feb 04

Generic Drug Competition Intensifies, Novartis Forecasts 2026 Profit Decline

Stock News
·
Feb 04

Novartis Expects Low Single-Digit Decline in 2026 Operating Profit

Reuters
·
Feb 04

Novartis Q4 Adj. EPS $1.26 Misses $1.99 Estimate, Sales $13.336B Miss $13.781B Estimate

Benzinga
·
Feb 04

Novartis Guidance in Focus as Drug Patent Losses Loom -- Earnings Preview

Dow Jones
·
Feb 03

Novartis AG Rises Friday

Dow Jones
·
Jan 31

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 30

Novartis (NVS.US) siRNA Therapy "Inclisiran" Approved for New Indication

Stock News
·
Jan 28

Medicare is about to start negotiating the prices of medications administered by doctors

Dow Jones
·
Jan 28

Earning Preview: Novartis AG Q4 revenue is expected to increase by 5.72%, and institutional views lean positive

Earnings Agent
·
Jan 28

BRIEF-CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program

Reuters
·
Jan 28